| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 69 | 2024 | 388 | 5.480 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 36 | 2022 | 196 | 3.550 |
Why?
|
| Dental Caries | 12 | 2022 | 14 | 2.230 |
Why?
|
| Medication Adherence | 8 | 2016 | 239 | 2.090 |
Why?
|
| Male | 188 | 2024 | 9843 | 2.060 |
Why?
|
| Middle Aged | 160 | 2024 | 7885 | 2.020 |
Why?
|
| Humans | 246 | 2024 | 17376 | 1.990 |
Why?
|
| Spirometry | 33 | 2024 | 65 | 1.860 |
Why?
|
| Hypertension | 33 | 2013 | 469 | 1.830 |
Why?
|
| Female | 186 | 2024 | 12444 | 1.780 |
Why?
|
| Forced Expiratory Volume | 38 | 2024 | 69 | 1.730 |
Why?
|
| Adult | 150 | 2024 | 7529 | 1.650 |
Why?
|
| Aged | 102 | 2024 | 6129 | 1.590 |
Why?
|
| Weight Loss | 18 | 2022 | 295 | 1.530 |
Why?
|
| Smoking | 33 | 2017 | 428 | 1.420 |
Why?
|
| Blood Pressure | 26 | 2014 | 275 | 1.300 |
Why?
|
| Lung | 14 | 2024 | 60 | 1.220 |
Why?
|
| Vital Capacity | 25 | 2024 | 35 | 1.170 |
Why?
|
| Anti-Asthmatic Agents | 13 | 2015 | 86 | 1.160 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2017 | 316 | 1.150 |
Why?
|
| Reminder Systems | 5 | 2016 | 74 | 1.140 |
Why?
|
| Health Maintenance Organizations | 21 | 2016 | 408 | 1.120 |
Why?
|
| Surveys and Questionnaires | 42 | 2019 | 1287 | 1.110 |
Why?
|
| Cardiovascular Diseases | 10 | 2022 | 533 | 1.100 |
Why?
|
| Occupational Exposure | 11 | 2017 | 67 | 1.020 |
Why?
|
| Xylitol | 6 | 2016 | 6 | 1.010 |
Why?
|
| Adrenal Cortex Hormones | 10 | 2015 | 68 | 0.980 |
Why?
|
| Cardiovascular Agents | 2 | 2016 | 22 | 0.960 |
Why?
|
| Research Design | 13 | 2021 | 343 | 0.920 |
Why?
|
| Diet, Sodium-Restricted | 12 | 2010 | 24 | 0.920 |
Why?
|
| Sex Factors | 24 | 2017 | 607 | 0.920 |
Why?
|
| Sweetening Agents | 5 | 2016 | 9 | 0.900 |
Why?
|
| Quality of Life | 16 | 2017 | 505 | 0.860 |
Why?
|
| Obesity | 12 | 2016 | 814 | 0.840 |
Why?
|
| Cross-Sectional Studies | 36 | 2024 | 1287 | 0.780 |
Why?
|
| Root Caries | 6 | 2016 | 6 | 0.780 |
Why?
|
| Adolescent | 51 | 2024 | 3533 | 0.750 |
Why?
|
| Patient Compliance | 16 | 2016 | 278 | 0.740 |
Why?
|
| Exercise | 9 | 2013 | 513 | 0.740 |
Why?
|
| Cariostatic Agents | 5 | 2013 | 5 | 0.740 |
Why?
|
| Age Factors | 21 | 2024 | 884 | 0.680 |
Why?
|
| Aged, 80 and over | 29 | 2019 | 1942 | 0.680 |
Why?
|
| Patient Education as Topic | 8 | 2016 | 193 | 0.670 |
Why?
|
| Electronic Health Records | 10 | 2020 | 707 | 0.650 |
Why?
|
| Acceleration | 2 | 2009 | 5 | 0.630 |
Why?
|
| Risk Factors | 44 | 2019 | 3255 | 0.580 |
Why?
|
| Prevalence | 27 | 2019 | 839 | 0.580 |
Why?
|
| Emergency Service, Hospital | 9 | 2024 | 381 | 0.570 |
Why?
|
| United States | 34 | 2020 | 3891 | 0.570 |
Why?
|
| Diet | 13 | 2009 | 356 | 0.560 |
Why?
|
| Health Promotion | 4 | 2016 | 278 | 0.560 |
Why?
|
| Colorectal Neoplasms | 6 | 2020 | 627 | 0.560 |
Why?
|
| Treatment Outcome | 25 | 2017 | 1170 | 0.550 |
Why?
|
| Health Services | 4 | 2006 | 112 | 0.540 |
Why?
|
| Respiratory Function Tests | 12 | 2012 | 32 | 0.540 |
Why?
|
| Pharmaceutical Services | 3 | 2012 | 34 | 0.530 |
Why?
|
| Occupational Diseases | 5 | 2017 | 38 | 0.530 |
Why?
|
| Health Literacy | 2 | 2016 | 38 | 0.530 |
Why?
|
| Drug Costs | 2 | 2016 | 32 | 0.510 |
Why?
|
| Overweight | 5 | 2013 | 266 | 0.500 |
Why?
|
| Medical Informatics | 2 | 2016 | 35 | 0.490 |
Why?
|
| Respiratory Tract Diseases | 5 | 2017 | 24 | 0.490 |
Why?
|
| Motor Activity | 7 | 2013 | 208 | 0.490 |
Why?
|
| Oregon | 19 | 2019 | 172 | 0.490 |
Why?
|
| Hospitalization | 14 | 2014 | 805 | 0.480 |
Why?
|
| Early Detection of Cancer | 6 | 2019 | 529 | 0.470 |
Why?
|
| Chlorhexidine | 3 | 2013 | 3 | 0.470 |
Why?
|
| Glucocorticoids | 4 | 2015 | 23 | 0.470 |
Why?
|
| Telephone | 4 | 2015 | 150 | 0.460 |
Why?
|
| Anticholesteremic Agents | 1 | 2014 | 13 | 0.460 |
Why?
|
| Mantodea | 1 | 2014 | 1 | 0.450 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 44 | 0.450 |
Why?
|
| Reproducibility of Results | 11 | 2012 | 367 | 0.440 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2011 | 2 | 0.440 |
Why?
|
| Managed Care Programs | 6 | 2012 | 309 | 0.440 |
Why?
|
| Severity of Illness Index | 14 | 2017 | 439 | 0.430 |
Why?
|
| Bronchodilator Agents | 7 | 2014 | 22 | 0.430 |
Why?
|
| Health Behavior | 8 | 2011 | 345 | 0.420 |
Why?
|
| Mass Screening | 6 | 2020 | 671 | 0.410 |
Why?
|
| Life Style | 10 | 2013 | 316 | 0.410 |
Why?
|
| Longitudinal Studies | 17 | 2013 | 677 | 0.400 |
Why?
|
| Adrenergic beta-Agonists | 6 | 2015 | 33 | 0.390 |
Why?
|
| Retrospective Studies | 17 | 2024 | 2428 | 0.390 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2014 | 380 | 0.390 |
Why?
|
| Predictive Value of Tests | 12 | 2016 | 342 | 0.390 |
Why?
|
| Antineoplastic Agents | 7 | 1999 | 58 | 0.390 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2022 | 666 | 0.390 |
Why?
|
| Monitoring, Ambulatory | 2 | 2009 | 18 | 0.390 |
Why?
|
| African Americans | 11 | 2016 | 443 | 0.380 |
Why?
|
| Child | 27 | 2018 | 2382 | 0.380 |
Why?
|
| Lung Diseases, Obstructive | 8 | 2013 | 11 | 0.380 |
Why?
|
| Leukotriene Antagonists | 4 | 2015 | 12 | 0.380 |
Why?
|
| Sickness Impact Profile | 3 | 2008 | 25 | 0.380 |
Why?
|
| Cohort Studies | 22 | 2017 | 2526 | 0.370 |
Why?
|
| Teaching | 1 | 2011 | 13 | 0.370 |
Why?
|
| Patient Selection | 4 | 2016 | 178 | 0.360 |
Why?
|
| Lung Diseases | 6 | 2013 | 41 | 0.360 |
Why?
|
| Clinical Trials as Topic | 8 | 2017 | 120 | 0.360 |
Why?
|
| Health Status | 6 | 2009 | 295 | 0.350 |
Why?
|
| Young Adult | 15 | 2024 | 2473 | 0.350 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2009 | 11 | 0.340 |
Why?
|
| Incidence | 15 | 2022 | 1266 | 0.340 |
Why?
|
| Time Factors | 17 | 2016 | 1044 | 0.340 |
Why?
|
| Monitoring, Physiologic | 3 | 2009 | 36 | 0.330 |
Why?
|
| Double-Blind Method | 7 | 2016 | 142 | 0.330 |
Why?
|
| Logistic Models | 14 | 2017 | 884 | 0.330 |
Why?
|
| Prospective Studies | 11 | 2017 | 1229 | 0.320 |
Why?
|
| Internet | 2 | 2010 | 212 | 0.320 |
Why?
|
| Weight Reduction Programs | 3 | 2016 | 49 | 0.320 |
Why?
|
| Prediabetic State | 2 | 2021 | 52 | 0.310 |
Why?
|
| Child, Preschool | 19 | 2017 | 1375 | 0.310 |
Why?
|
| Cost-Benefit Analysis | 6 | 2022 | 226 | 0.310 |
Why?
|
| Administration, Inhalation | 7 | 2016 | 39 | 0.300 |
Why?
|
| Follow-Up Studies | 13 | 2017 | 1155 | 0.290 |
Why?
|
| Nurses | 6 | 1999 | 34 | 0.290 |
Why?
|
| Authorship | 1 | 2007 | 5 | 0.290 |
Why?
|
| Publishing | 1 | 2007 | 8 | 0.290 |
Why?
|
| Safety-net Providers | 3 | 2019 | 55 | 0.290 |
Why?
|
| Automobile Driving | 2 | 2017 | 10 | 0.280 |
Why?
|
| Antitubercular Agents | 2 | 2020 | 9 | 0.280 |
Why?
|
| Peak Expiratory Flow Rate | 5 | 2012 | 13 | 0.280 |
Why?
|
| Tobacco Smoking | 2 | 2017 | 19 | 0.280 |
Why?
|
| DMF Index | 6 | 2013 | 6 | 0.280 |
Why?
|
| Regression Analysis | 7 | 2014 | 280 | 0.270 |
Why?
|
| Sodium | 4 | 2013 | 13 | 0.270 |
Why?
|
| Ethnic Groups | 4 | 2008 | 456 | 0.270 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2022 | 537 | 0.270 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2016 | 9 | 0.270 |
Why?
|
| Sodium, Dietary | 5 | 2010 | 10 | 0.270 |
Why?
|
| Multicenter Studies as Topic | 9 | 2016 | 81 | 0.260 |
Why?
|
| Risk Assessment | 7 | 2014 | 1079 | 0.260 |
Why?
|
| Social Support | 2 | 2013 | 208 | 0.260 |
Why?
|
| Body Mass Index | 10 | 2018 | 937 | 0.260 |
Why?
|
| Acupuncture Therapy | 2 | 2017 | 32 | 0.250 |
Why?
|
| Colonic Neoplasms | 2 | 2020 | 163 | 0.250 |
Why?
|
| Musculoskeletal Pain | 2 | 2017 | 24 | 0.250 |
Why?
|
| Body Weight | 6 | 2013 | 203 | 0.250 |
Why?
|
| Pharmacists | 5 | 1999 | 48 | 0.240 |
Why?
|
| Continental Population Groups | 3 | 2013 | 289 | 0.240 |
Why?
|
| Cost Sharing | 2 | 2016 | 29 | 0.240 |
Why?
|
| Data Collection | 3 | 2009 | 240 | 0.240 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2005 | 53 | 0.230 |
Why?
|
| Occult Blood | 4 | 2019 | 155 | 0.230 |
Why?
|
| Disease Progression | 8 | 2024 | 259 | 0.230 |
Why?
|
| Program Evaluation | 5 | 2016 | 215 | 0.230 |
Why?
|
| Biomedical Research | 2 | 2017 | 75 | 0.220 |
Why?
|
| Poverty | 3 | 2014 | 165 | 0.220 |
Why?
|
| Office Visits | 1 | 2005 | 74 | 0.220 |
Why?
|
| Crime | 1 | 2024 | 22 | 0.220 |
Why?
|
| Feces | 3 | 2020 | 85 | 0.220 |
Why?
|
| Aging | 6 | 2004 | 160 | 0.220 |
Why?
|
| Dyspnea | 5 | 2017 | 48 | 0.210 |
Why?
|
| Feeding Behavior | 4 | 2013 | 163 | 0.210 |
Why?
|
| Specialization | 2 | 2005 | 21 | 0.210 |
Why?
|
| Disasters | 5 | 1989 | 6 | 0.210 |
Why?
|
| Socioeconomic Factors | 4 | 2024 | 609 | 0.210 |
Why?
|
| Allergy and Immunology | 2 | 2005 | 4 | 0.200 |
Why?
|
| Tooth | 1 | 2022 | 1 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 165 | 0.200 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2020 | 8 | 0.200 |
Why?
|
| Air Pollutants, Occupational | 2 | 2016 | 16 | 0.200 |
Why?
|
| Albuterol | 2 | 2016 | 7 | 0.200 |
Why?
|
| Northwestern United States | 7 | 2016 | 53 | 0.200 |
Why?
|
| Algorithms | 7 | 2018 | 226 | 0.190 |
Why?
|
| Residence Characteristics | 1 | 2024 | 253 | 0.190 |
Why?
|
| Biomarkers | 2 | 2016 | 306 | 0.190 |
Why?
|
| Analysis of Variance | 4 | 2011 | 140 | 0.190 |
Why?
|
| Drug Prescriptions | 3 | 2015 | 148 | 0.190 |
Why?
|
| Behavior Therapy | 4 | 2016 | 126 | 0.190 |
Why?
|
| Comparative Effectiveness Research | 2 | 2012 | 63 | 0.190 |
Why?
|
| Cost of Illness | 4 | 2017 | 93 | 0.190 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2020 | 5 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2016 | 366 | 0.190 |
Why?
|
| Propensity Score | 3 | 2017 | 82 | 0.180 |
Why?
|
| Europe | 6 | 2024 | 46 | 0.180 |
Why?
|
| Albuminuria | 2 | 2013 | 35 | 0.180 |
Why?
|
| Toothbrushing | 3 | 2016 | 3 | 0.180 |
Why?
|
| Population Surveillance | 3 | 2014 | 254 | 0.170 |
Why?
|
| Weight Gain | 2 | 2013 | 156 | 0.170 |
Why?
|
| Ambulatory Care | 3 | 2017 | 228 | 0.170 |
Why?
|
| Models, Statistical | 3 | 2010 | 173 | 0.170 |
Why?
|
| Outcome Assessment (Health Care) | 5 | 2010 | 216 | 0.160 |
Why?
|
| Cough | 5 | 2017 | 22 | 0.160 |
Why?
|
| Medical History Taking | 2 | 2009 | 33 | 0.160 |
Why?
|
| Family Health | 2 | 2009 | 45 | 0.160 |
Why?
|
| Health Status Indicators | 4 | 2012 | 60 | 0.160 |
Why?
|
| Bronchitis, Chronic | 2 | 2017 | 4 | 0.160 |
Why?
|
| Chronic Disease | 9 | 2015 | 405 | 0.160 |
Why?
|
| Lipids | 2 | 2014 | 69 | 0.160 |
Why?
|
| Sex Distribution | 7 | 2017 | 180 | 0.150 |
Why?
|
| Decision Making | 2 | 2011 | 172 | 0.150 |
Why?
|
| Models, Theoretical | 3 | 2016 | 66 | 0.150 |
Why?
|
| Age Distribution | 7 | 2017 | 239 | 0.150 |
Why?
|
| Health Services Accessibility | 2 | 2019 | 274 | 0.150 |
Why?
|
| Health Care Costs | 1 | 2020 | 211 | 0.150 |
Why?
|
| Oral Health | 2 | 2016 | 17 | 0.150 |
Why?
|
| Odds Ratio | 8 | 2019 | 644 | 0.150 |
Why?
|
| Energy Intake | 4 | 2013 | 98 | 0.150 |
Why?
|
| Colonoscopy | 2 | 2018 | 257 | 0.150 |
Why?
|
| Animals | 3 | 2014 | 280 | 0.150 |
Why?
|
| Drug Utilization | 4 | 2007 | 122 | 0.150 |
Why?
|
| Dental Plaque | 1 | 2018 | 1 | 0.150 |
Why?
|
| Streptococcus gordonii | 1 | 2018 | 1 | 0.150 |
Why?
|
| Biofilms | 1 | 2018 | 2 | 0.150 |
Why?
|
| Community Health Centers | 1 | 2019 | 64 | 0.150 |
Why?
|
| Pit and Fissure Sealants | 3 | 2013 | 3 | 0.150 |
Why?
|
| Bacterial Proteins | 1 | 2018 | 13 | 0.140 |
Why?
|
| Immunoglobulin E | 3 | 2000 | 5 | 0.140 |
Why?
|
| Income | 2 | 2017 | 87 | 0.140 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 30 | 0.140 |
Why?
|
| Activities of Daily Living | 2 | 2014 | 82 | 0.140 |
Why?
|
| Poisson Distribution | 3 | 2011 | 85 | 0.140 |
Why?
|
| Crowns | 3 | 2013 | 3 | 0.140 |
Why?
|
| Dental Enamel | 3 | 2013 | 3 | 0.140 |
Why?
|
| Dental Restoration, Permanent | 3 | 2013 | 3 | 0.140 |
Why?
|
| Dentin | 3 | 2013 | 3 | 0.140 |
Why?
|
| Linear Models | 5 | 2017 | 210 | 0.140 |
Why?
|
| Outcome and Process Assessment (Health Care) | 3 | 2008 | 98 | 0.140 |
Why?
|
| Unemployment | 1 | 2017 | 12 | 0.140 |
Why?
|
| Volatile Organic Compounds | 1 | 2017 | 2 | 0.140 |
Why?
|
| Cooking | 1 | 2017 | 17 | 0.140 |
Why?
|
| Smoke | 1 | 2017 | 6 | 0.140 |
Why?
|
| Random Allocation | 1 | 2017 | 33 | 0.140 |
Why?
|
| Psychometrics | 5 | 2014 | 119 | 0.140 |
Why?
|
| Health Resources | 2 | 2016 | 34 | 0.140 |
Why?
|
| Information Dissemination | 1 | 2017 | 51 | 0.140 |
Why?
|
| Family Practice | 1 | 1997 | 41 | 0.140 |
Why?
|
| Minority Groups | 1 | 1998 | 103 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 200 | 0.140 |
Why?
|
| Chlorofluorocarbons | 1 | 2016 | 2 | 0.130 |
Why?
|
| Fractures, Bone | 2 | 2008 | 94 | 0.130 |
Why?
|
| Antipsychotic Agents | 1 | 2017 | 49 | 0.130 |
Why?
|
| Medical Records Systems, Computerized | 3 | 2006 | 70 | 0.130 |
Why?
|
| Acute Disease | 5 | 2012 | 144 | 0.130 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 53 | 0.130 |
Why?
|
| Quality Control | 3 | 2011 | 42 | 0.130 |
Why?
|
| Outpatients | 1 | 2017 | 101 | 0.130 |
Why?
|
| European Continental Ancestry Group | 6 | 2011 | 480 | 0.130 |
Why?
|
| Primary Health Care | 4 | 2009 | 729 | 0.130 |
Why?
|
| Patient Satisfaction | 4 | 2009 | 198 | 0.130 |
Why?
|
| Reference Values | 6 | 2012 | 86 | 0.130 |
Why?
|
| Hypersensitivity | 2 | 2005 | 18 | 0.130 |
Why?
|
| Diet Surveys | 1 | 2016 | 56 | 0.130 |
Why?
|
| Demography | 2 | 2014 | 96 | 0.130 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 12 | 0.130 |
Why?
|
| Databases, Factual | 4 | 2006 | 306 | 0.130 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 8 | 0.130 |
Why?
|
| Models, Economic | 1 | 2016 | 17 | 0.130 |
Why?
|
| Motorcycles | 1 | 2016 | 5 | 0.130 |
Why?
|
| Occupational Health | 2 | 1993 | 16 | 0.130 |
Why?
|
| Dental Caries Susceptibility | 4 | 2022 | 4 | 0.130 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 41 | 0.120 |
Why?
|
| Health Surveys | 7 | 2013 | 250 | 0.120 |
Why?
|
| Survival Rate | 4 | 2013 | 253 | 0.120 |
Why?
|
| Sensitivity and Specificity | 7 | 2012 | 300 | 0.120 |
Why?
|
| Medical Record Linkage | 1 | 2016 | 37 | 0.120 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 42 | 0.120 |
Why?
|
| Glycated Hemoglobin A | 3 | 2022 | 184 | 0.120 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 538 | 0.120 |
Why?
|
| Manipulation, Chiropractic | 1 | 2015 | 18 | 0.120 |
Why?
|
| Infant | 7 | 2017 | 1162 | 0.120 |
Why?
|
| Depression | 3 | 2015 | 487 | 0.120 |
Why?
|
| Speech Recognition Software | 1 | 2015 | 2 | 0.120 |
Why?
|
| Drug Labeling | 1 | 2015 | 12 | 0.120 |
Why?
|
| Air Pollution | 1 | 2016 | 43 | 0.120 |
Why?
|
| Risk Reduction Behavior | 2 | 2008 | 104 | 0.120 |
Why?
|
| Clinical Pharmacy Information Systems | 3 | 2006 | 10 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 84 | 0.120 |
Why?
|
| Chronic Pain | 1 | 2017 | 127 | 0.120 |
Why?
|
| Churg-Strauss Syndrome | 2 | 2005 | 5 | 0.120 |
Why?
|
| Motivation | 2 | 2011 | 116 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 311 | 0.120 |
Why?
|
| United States Food and Drug Administration | 2 | 2015 | 32 | 0.120 |
Why?
|
| Angiography | 1 | 2014 | 12 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 455 | 0.120 |
Why?
|
| Physical Fitness | 3 | 2010 | 70 | 0.120 |
Why?
|
| Tuberculosis | 2 | 2013 | 24 | 0.120 |
Why?
|
| Postal Service | 3 | 2020 | 72 | 0.120 |
Why?
|
| Energy Metabolism | 3 | 2009 | 48 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1997 | 311 | 0.110 |
Why?
|
| Species Specificity | 1 | 2014 | 5 | 0.110 |
Why?
|
| Asia, Southeastern | 1 | 2014 | 4 | 0.110 |
Why?
|
| Hispanic Americans | 3 | 2015 | 378 | 0.110 |
Why?
|
| Statistics as Topic | 2 | 2011 | 57 | 0.110 |
Why?
|
| Developed Countries | 2 | 2017 | 5 | 0.110 |
Why?
|
| Pulmonary Emphysema | 4 | 2005 | 11 | 0.110 |
Why?
|
| National Institute of Dental and Craniofacial Research (U.S.) | 2 | 2010 | 2 | 0.110 |
Why?
|
| Developing Countries | 2 | 2017 | 13 | 0.110 |
Why?
|
| Suicide, Attempted | 1 | 2015 | 92 | 0.110 |
Why?
|
| Receptors, GABA-A | 1 | 2013 | 1 | 0.110 |
Why?
|
| Central Nervous System Depressants | 1 | 2013 | 2 | 0.110 |
Why?
|
| Directly Observed Therapy | 1 | 2013 | 1 | 0.110 |
Why?
|
| Cerebellum | 1 | 2013 | 2 | 0.110 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 1 | 2013 | 5 | 0.110 |
Why?
|
| Comorbidity | 4 | 2022 | 564 | 0.110 |
Why?
|
| Urban Health Services | 1 | 2013 | 11 | 0.110 |
Why?
|
| Interviews as Topic | 4 | 2008 | 304 | 0.110 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 34 | 0.110 |
Why?
|
| Poverty Areas | 1 | 2013 | 21 | 0.110 |
Why?
|
| Ethanol | 1 | 2013 | 21 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2020 | 1100 | 0.110 |
Why?
|
| Smoking Cessation | 2 | 2011 | 154 | 0.110 |
Why?
|
| Nigeria | 3 | 2017 | 3 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2013 | 44 | 0.110 |
Why?
|
| Phosphorus, Dietary | 1 | 2013 | 1 | 0.110 |
Why?
|
| Program Development | 1 | 1994 | 64 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 203 | 0.100 |
Why?
|
| Obesity, Abdominal | 1 | 2013 | 11 | 0.100 |
Why?
|
| Hawaii | 2 | 2012 | 58 | 0.100 |
Why?
|
| Diet Records | 4 | 2011 | 37 | 0.100 |
Why?
|
| Child Health Services | 1 | 2014 | 106 | 0.100 |
Why?
|
| Prehypertension | 1 | 2013 | 21 | 0.100 |
Why?
|
| Renal Dialysis | 2 | 1983 | 57 | 0.100 |
Why?
|
| Developmental Disabilities | 1 | 2013 | 52 | 0.100 |
Why?
|
| Mental Health Services | 1 | 2015 | 154 | 0.100 |
Why?
|
| Episode of Care | 1 | 1993 | 11 | 0.100 |
Why?
|
| Community Health Services | 1 | 2013 | 79 | 0.100 |
Why?
|
| Observer Variation | 2 | 2011 | 36 | 0.100 |
Why?
|
| Mental Disorders | 2 | 1986 | 273 | 0.100 |
Why?
|
| Self Care | 2 | 2012 | 145 | 0.100 |
Why?
|
| Total Lung Capacity | 1 | 2012 | 2 | 0.100 |
Why?
|
| Placebos | 4 | 2013 | 19 | 0.100 |
Why?
|
| Patient Care Management | 1 | 2012 | 26 | 0.100 |
Why?
|
| Coronary Disease | 3 | 2003 | 146 | 0.100 |
Why?
|
| Health Personnel | 1 | 1994 | 126 | 0.100 |
Why?
|
| Geography | 3 | 2013 | 39 | 0.100 |
Why?
|
| Global Health | 4 | 2013 | 29 | 0.100 |
Why?
|
| Fruit | 7 | 2009 | 80 | 0.100 |
Why?
|
| Vegetables | 7 | 2009 | 88 | 0.100 |
Why?
|
| Forced Expiratory Flow Rates | 2 | 2011 | 2 | 0.100 |
Why?
|
| Bronchitis | 3 | 1998 | 5 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 2 | 1983 | 151 | 0.090 |
Why?
|
| Process Assessment (Health Care) | 1 | 2012 | 23 | 0.090 |
Why?
|
| Teaching Materials | 1 | 2011 | 4 | 0.090 |
Why?
|
| Telemedicine | 1 | 2015 | 182 | 0.090 |
Why?
|
| Calibration | 1 | 2011 | 7 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1991 | 21 | 0.090 |
Why?
|
| Family | 1 | 1992 | 106 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2011 | 231 | 0.090 |
Why?
|
| Diabetic Angiopathies | 1 | 2011 | 31 | 0.090 |
Why?
|
| Rural Population | 2 | 2020 | 55 | 0.090 |
Why?
|
| Adrenergic Fibers | 1 | 2010 | 1 | 0.090 |
Why?
|
| Sympathetic Nervous System | 1 | 2010 | 3 | 0.090 |
Why?
|
| Educational Status | 3 | 2017 | 179 | 0.090 |
Why?
|
| Urban Population | 2 | 2020 | 109 | 0.090 |
Why?
|
| Streptococcus mutans | 1 | 2010 | 1 | 0.090 |
Why?
|
| Health Policy | 1 | 2011 | 109 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2010 | 372 | 0.090 |
Why?
|
| Renin-Angiotensin System | 1 | 2010 | 16 | 0.090 |
Why?
|
| Lung Volume Measurements | 1 | 1990 | 2 | 0.090 |
Why?
|
| California | 4 | 2024 | 2317 | 0.090 |
Why?
|
| Medical Audit | 2 | 2005 | 36 | 0.090 |
Why?
|
| Patient Discharge | 1 | 1992 | 154 | 0.090 |
Why?
|
| Interpersonal Relations | 1 | 2010 | 41 | 0.080 |
Why?
|
| Likelihood Functions | 3 | 2017 | 45 | 0.080 |
Why?
|
| Circadian Rhythm | 3 | 2005 | 17 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 134 | 0.080 |
Why?
|
| Bone Density Conservation Agents | 2 | 2008 | 56 | 0.080 |
Why?
|
| Delivery of Health Care | 2 | 2011 | 395 | 0.080 |
Why?
|
| Body Constitution | 3 | 2002 | 39 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 3 | 2011 | 33 | 0.080 |
Why?
|
| Washington | 5 | 2019 | 385 | 0.080 |
Why?
|
| Rhinitis | 1 | 2009 | 2 | 0.080 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2009 | 7 | 0.080 |
Why?
|
| Nitric Oxide | 1 | 2009 | 10 | 0.080 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2009 | 8 | 0.080 |
Why?
|
| Hypoxia | 1 | 2009 | 8 | 0.080 |
Why?
|
| Food | 1 | 1999 | 36 | 0.080 |
Why?
|
| Parents | 4 | 2015 | 287 | 0.080 |
Why?
|
| Respiratory Sounds | 2 | 2013 | 12 | 0.080 |
Why?
|
| Cause of Death | 2 | 1989 | 175 | 0.080 |
Why?
|
| Administration, Oral | 4 | 2013 | 83 | 0.080 |
Why?
|
| Muscle Strength | 1 | 2009 | 12 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 4 | 2017 | 74 | 0.080 |
Why?
|
| Exercise Test | 1 | 2009 | 45 | 0.080 |
Why?
|
| Fluorides | 3 | 2013 | 3 | 0.080 |
Why?
|
| Air Pollutants | 2 | 1986 | 53 | 0.080 |
Why?
|
| Patient Participation | 1 | 2009 | 123 | 0.070 |
Why?
|
| Medicare | 2 | 2020 | 201 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2006 | 203 | 0.070 |
Why?
|
| Marijuana Smoking | 1 | 2009 | 52 | 0.070 |
Why?
|
| Medicaid | 2 | 2020 | 184 | 0.070 |
Why?
|
| Dental Care | 2 | 2022 | 16 | 0.070 |
Why?
|
| Heart Rate | 2 | 2007 | 38 | 0.070 |
Why?
|
| Airway Obstruction | 3 | 2017 | 4 | 0.070 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2016 | 26 | 0.070 |
Why?
|
| Scientific Misconduct | 1 | 2007 | 1 | 0.070 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2008 | 42 | 0.070 |
Why?
|
| Peer Review | 1 | 2007 | 4 | 0.070 |
Why?
|
| Dust | 5 | 2008 | 22 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 100 | 0.070 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 104 | 0.070 |
Why?
|
| Colorado | 3 | 2017 | 164 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2007 | 77 | 0.070 |
Why?
|
| Sick Role | 1 | 2006 | 9 | 0.070 |
Why?
|
| Communication | 1 | 2008 | 181 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2006 | 124 | 0.060 |
Why?
|
| Australia | 3 | 2013 | 25 | 0.060 |
Why?
|
| Self Concept | 1 | 2006 | 39 | 0.060 |
Why?
|
| China | 3 | 2002 | 132 | 0.060 |
Why?
|
| Adenoviridae Infections | 1 | 2006 | 1 | 0.060 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2006 | 2 | 0.060 |
Why?
|
| Eye Diseases | 1 | 1986 | 6 | 0.060 |
Why?
|
| Bone Density | 3 | 2008 | 94 | 0.060 |
Why?
|
| Isoproterenol | 1 | 1985 | 1 | 0.060 |
Why?
|
| Internationality | 2 | 2017 | 13 | 0.060 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2016 | 25 | 0.060 |
Why?
|
| Self Report | 2 | 2017 | 257 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2008 | 279 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 114 | 0.060 |
Why?
|
| Pharmacoepidemiology | 2 | 2003 | 18 | 0.060 |
Why?
|
| Cesarean Section | 1 | 2005 | 33 | 0.060 |
Why?
|
| Nutritional Physiological Phenomena | 2 | 1999 | 14 | 0.060 |
Why?
|
| Patient Admission | 3 | 1999 | 69 | 0.060 |
Why?
|
| Dietary Fats | 3 | 2001 | 89 | 0.060 |
Why?
|
| Africa | 1 | 2024 | 5 | 0.060 |
Why?
|
| Principal Component Analysis | 1 | 2024 | 24 | 0.060 |
Why?
|
| Directive Counseling | 1 | 2005 | 23 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2005 | 40 | 0.060 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2004 | 4 | 0.060 |
Why?
|
| Tooth Crown | 2 | 2015 | 2 | 0.060 |
Why?
|
| Insurance, Health | 2 | 2017 | 175 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 702 | 0.060 |
Why?
|
| Emigration and Immigration | 1 | 2004 | 14 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 37 | 0.050 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2003 | 9 | 0.050 |
Why?
|
| Attitude to Health | 2 | 2011 | 148 | 0.050 |
Why?
|
| Tooth Root | 2 | 2015 | 2 | 0.050 |
Why?
|
| Sampling Studies | 4 | 2007 | 44 | 0.050 |
Why?
|
| Hypersensitivity, Immediate | 2 | 2000 | 5 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2014 | 211 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2003 | 18 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 1983 | 30 | 0.050 |
Why?
|
| Antioxidants | 1 | 2003 | 40 | 0.050 |
Why?
|
| Practice Patterns, Dentists' | 1 | 2022 | 3 | 0.050 |
Why?
|
| Metered Dose Inhalers | 2 | 2016 | 5 | 0.050 |
Why?
|
| Morbidity | 2 | 1994 | 59 | 0.050 |
Why?
|
| Dyslipidemias | 2 | 2013 | 56 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 1989 | 67 | 0.050 |
Why?
|
| Tooth Loss | 2 | 2013 | 2 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2004 | 160 | 0.050 |
Why?
|
| Pulmonary Medicine | 3 | 2012 | 19 | 0.050 |
Why?
|
| Food Hypersensitivity | 2 | 2005 | 6 | 0.050 |
Why?
|
| Patient Care | 1 | 2002 | 30 | 0.050 |
Why?
|
| Back Injuries | 2 | 1993 | 4 | 0.050 |
Why?
|
| Accidents, Occupational | 2 | 1993 | 6 | 0.050 |
Why?
|
| Emergency Medical Services | 1 | 2002 | 48 | 0.050 |
Why?
|
| Registries | 1 | 2004 | 460 | 0.050 |
Why?
|
| Body Height | 2 | 1995 | 60 | 0.050 |
Why?
|
| Alabama | 2 | 2011 | 23 | 0.050 |
Why?
|
| North Carolina | 2 | 2011 | 34 | 0.050 |
Why?
|
| Infant, Newborn | 3 | 2015 | 805 | 0.040 |
Why?
|
| Forecasting | 4 | 2009 | 69 | 0.040 |
Why?
|
| Kidney Diseases | 2 | 2013 | 51 | 0.040 |
Why?
|
| Triglycerides | 1 | 2001 | 83 | 0.040 |
Why?
|
| India | 1 | 2020 | 12 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 16 | 0.040 |
Why?
|
| Seasons | 2 | 2000 | 113 | 0.040 |
Why?
|
| BCG Vaccine | 1 | 2000 | 8 | 0.040 |
Why?
|
| Risk | 3 | 2014 | 498 | 0.040 |
Why?
|
| Cross-Over Studies | 3 | 2007 | 47 | 0.040 |
Why?
|
| Food Analysis | 1 | 1999 | 5 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2000 | 51 | 0.040 |
Why?
|
| Urine | 1 | 1999 | 5 | 0.040 |
Why?
|
| Fetal Death | 1 | 1999 | 8 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 2000 | 55 | 0.040 |
Why?
|
| Focus Groups | 2 | 2011 | 144 | 0.040 |
Why?
|
| Diet, Reducing | 2 | 2013 | 22 | 0.040 |
Why?
|
| New Zealand | 2 | 1997 | 7 | 0.040 |
Why?
|
| Prognosis | 3 | 2009 | 604 | 0.040 |
Why?
|
| Abortion, Spontaneous | 1 | 1999 | 49 | 0.040 |
Why?
|
| Norway | 3 | 2005 | 5 | 0.040 |
Why?
|
| Respiration, Artificial | 2 | 2006 | 36 | 0.040 |
Why?
|
| Dairy Products | 3 | 2007 | 23 | 0.040 |
Why?
|
| Hospitals | 1 | 1999 | 76 | 0.040 |
Why?
|
| Theophylline | 2 | 2009 | 3 | 0.040 |
Why?
|
| Mutagenicity Tests | 1 | 1998 | 1 | 0.040 |
Why?
|
| Diet, Fat-Restricted | 2 | 2009 | 36 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 1998 | 47 | 0.040 |
Why?
|
| Regulon | 1 | 2018 | 1 | 0.040 |
Why?
|
| Phosphotransferases | 1 | 2018 | 2 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2018 | 2 | 0.040 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2018 | 2 | 0.040 |
Why?
|
| Genes, Bacterial | 1 | 2018 | 3 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 10 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2018 | 15 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2018 | 9 | 0.040 |
Why?
|
| Arginine | 1 | 2018 | 12 | 0.040 |
Why?
|
| Pregnancy | 3 | 2013 | 1466 | 0.040 |
Why?
|
| Patient Care Team | 1 | 1999 | 107 | 0.040 |
Why?
|
| Stress, Psychological | 2 | 2012 | 133 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 1988 | 72 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 35 | 0.040 |
Why?
|
| Environmental Exposure | 4 | 2005 | 119 | 0.040 |
Why?
|
| Confounding Factors (Epidemiology) | 2 | 2014 | 84 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 1998 | 52 | 0.040 |
Why?
|
| Tobacco | 1 | 2017 | 11 | 0.040 |
Why?
|
| Benzene | 1 | 2017 | 1 | 0.040 |
Why?
|
| Charcoal | 1 | 2017 | 1 | 0.040 |
Why?
|
| Kerosene | 1 | 2017 | 1 | 0.040 |
Why?
|
| Wood | 1 | 2017 | 1 | 0.040 |
Why?
|
| Patient-Centered Care | 2 | 2012 | 190 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 13 | 0.040 |
Why?
|
| Sample Size | 1 | 2017 | 27 | 0.030 |
Why?
|
| Confidentiality | 1 | 2017 | 25 | 0.030 |
Why?
|
| Intersectoral Collaboration | 1 | 2017 | 13 | 0.030 |
Why?
|
| Infertility | 1 | 1997 | 3 | 0.030 |
Why?
|
| Public Health | 1 | 2018 | 82 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 81 | 0.030 |
Why?
|
| Self Administration | 1 | 2016 | 8 | 0.030 |
Why?
|
| Respiration | 2 | 1987 | 6 | 0.030 |
Why?
|
| Soil | 1 | 2016 | 2 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 3 | 1991 | 30 | 0.030 |
Why?
|
| Immunization | 1 | 2017 | 69 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2016 | 55 | 0.030 |
Why?
|
| Biostatistics | 1 | 2016 | 11 | 0.030 |
Why?
|
| Benin | 1 | 2016 | 1 | 0.030 |
Why?
|
| Carbon Monoxide | 1 | 2016 | 7 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2012 | 108 | 0.030 |
Why?
|
| Vehicle Emissions | 1 | 2016 | 23 | 0.030 |
Why?
|
| Protective Clothing | 2 | 1993 | 2 | 0.030 |
Why?
|
| Pneumonia | 2 | 1996 | 49 | 0.030 |
Why?
|
| Respiratory Mechanics | 1 | 1995 | 1 | 0.030 |
Why?
|
| Anxiety Disorders | 2 | 1986 | 92 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 19 | 0.030 |
Why?
|
| Databases as Topic | 2 | 2005 | 19 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 1995 | 65 | 0.030 |
Why?
|
| Body Composition | 1 | 1995 | 91 | 0.030 |
Why?
|
| Physician-Patient Relations | 2 | 2009 | 169 | 0.030 |
Why?
|
| Rhinitis, Allergic | 1 | 2014 | 4 | 0.030 |
Why?
|
| Health Care Reform | 1 | 2014 | 20 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 40 | 0.030 |
Why?
|
| Social Behavior | 1 | 2014 | 21 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2014 | 41 | 0.030 |
Why?
|
| Fatigue | 1 | 2014 | 32 | 0.030 |
Why?
|
| Depressive Disorder | 2 | 1986 | 185 | 0.030 |
Why?
|
| Allergens | 2 | 2000 | 7 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 86 | 0.030 |
Why?
|
| Isoxazoles | 1 | 2013 | 1 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 2013 | 1 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 8 | 0.030 |
Why?
|
| Brazil | 1 | 2013 | 10 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2013 | 17 | 0.030 |
Why?
|
| United Kingdom | 1 | 2013 | 25 | 0.030 |
Why?
|
| Community Health Workers | 1 | 2013 | 13 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 1994 | 24 | 0.030 |
Why?
|
| Rats | 1 | 2013 | 35 | 0.030 |
Why?
|
| Sleep | 1 | 2014 | 57 | 0.030 |
Why?
|
| Disease Notification | 1 | 2013 | 7 | 0.030 |
Why?
|
| Sucrose | 1 | 2013 | 6 | 0.030 |
Why?
|
| Neurons | 1 | 2013 | 10 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2013 | 14 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 1994 | 27 | 0.030 |
Why?
|
| Sputum | 1 | 2013 | 4 | 0.030 |
Why?
|
| Phosphorus | 1 | 2013 | 6 | 0.030 |
Why?
|
| Potassium | 1 | 2013 | 15 | 0.030 |
Why?
|
| Fluorides, Topical | 1 | 2013 | 1 | 0.030 |
Why?
|
| Toothpastes | 1 | 2013 | 1 | 0.030 |
Why?
|
| Tablets | 1 | 2013 | 2 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2013 | 33 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 1993 | 14 | 0.030 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 1993 | 8 | 0.030 |
Why?
|
| Pharmacy Service, Hospital | 1 | 1993 | 4 | 0.030 |
Why?
|
| Nursing, Practical | 1 | 1993 | 1 | 0.030 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 1993 | 2 | 0.030 |
Why?
|
| Personnel, Hospital | 1 | 1993 | 9 | 0.030 |
Why?
|
| Mortality | 1 | 1994 | 116 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 1993 | 9 | 0.030 |
Why?
|
| Nursing Staff, Hospital | 1 | 1993 | 10 | 0.030 |
Why?
|
| Abdomen | 1 | 1993 | 20 | 0.030 |
Why?
|
| Morphine | 1 | 1993 | 8 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 1993 | 16 | 0.030 |
Why?
|
| Patient Advocacy | 1 | 2012 | 13 | 0.030 |
Why?
|
| Bias | 1 | 1993 | 100 | 0.030 |
Why?
|
| Mental Health | 1 | 2014 | 168 | 0.020 |
Why?
|
| Asian Americans | 2 | 1995 | 164 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2013 | 72 | 0.020 |
Why?
|
| Health Education | 1 | 1993 | 82 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 246 | 0.020 |
Why?
|
| Alcohol Drinking | 2 | 2007 | 355 | 0.020 |
Why?
|
| Dental Devices, Home Care | 1 | 2011 | 1 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2011 | 5 | 0.020 |
Why?
|
| Intubation, Gastrointestinal | 1 | 1991 | 1 | 0.020 |
Why?
|
| Pneumonia, Aspiration | 1 | 1991 | 2 | 0.020 |
Why?
|
| Translational Medical Research | 1 | 2012 | 33 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 86 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 1991 | 30 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2013 | 168 | 0.020 |
Why?
|
| Social Control, Informal | 1 | 2011 | 1 | 0.020 |
Why?
|
| Utilization Review | 2 | 2004 | 44 | 0.020 |
Why?
|
| Sweden | 1 | 2011 | 19 | 0.020 |
Why?
|
| Angiotensinogen | 1 | 2010 | 1 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2010 | 2 | 0.020 |
Why?
|
| Kallikreins | 1 | 2010 | 3 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2010 | 28 | 0.020 |
Why?
|
| Cumulative Trauma Disorders | 1 | 1990 | 2 | 0.020 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2010 | 1 | 0.020 |
Why?
|
| Nursing Care | 1 | 1990 | 4 | 0.020 |
Why?
|
| Critical Care | 1 | 1991 | 67 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2010 | 33 | 0.020 |
Why?
|
| Canada | 1 | 1990 | 70 | 0.020 |
Why?
|
| Texas | 1 | 2010 | 39 | 0.020 |
Why?
|
| Radiography | 2 | 2006 | 36 | 0.020 |
Why?
|
| Patient Readmission | 1 | 1992 | 165 | 0.020 |
Why?
|
| Cadmium Poisoning | 1 | 1990 | 1 | 0.020 |
Why?
|
| Sewage | 1 | 1990 | 1 | 0.020 |
Why?
|
| Soil Pollutants | 1 | 1990 | 1 | 0.020 |
Why?
|
| Food Contamination | 1 | 1990 | 3 | 0.020 |
Why?
|
| Foodborne Diseases | 1 | 1990 | 5 | 0.020 |
Why?
|
| Phenotype | 1 | 2010 | 148 | 0.020 |
Why?
|
| Beclomethasone | 1 | 2009 | 1 | 0.020 |
Why?
|
| Cromolyn Sodium | 1 | 2009 | 3 | 0.020 |
Why?
|
| African Continental Ancestry Group | 3 | 1999 | 144 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2011 | 262 | 0.020 |
Why?
|
| Argentina | 1 | 2009 | 1 | 0.020 |
Why?
|
| Genome, Human | 1 | 2009 | 34 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2011 | 148 | 0.020 |
Why?
|
| Counseling | 1 | 2011 | 173 | 0.020 |
Why?
|
| British Columbia | 1 | 2009 | 3 | 0.020 |
Why?
|
| Smoking Prevention | 1 | 2009 | 35 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 363 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 72 | 0.020 |
Why?
|
| Goals | 1 | 2009 | 28 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2009 | 63 | 0.020 |
Why?
|
| Marijuana Abuse | 1 | 2009 | 43 | 0.020 |
Why?
|
| Respiratory Protective Devices | 1 | 2008 | 3 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 171 | 0.020 |
Why?
|
| Nitrogen | 1 | 1988 | 1 | 0.020 |
Why?
|
| Breath Tests | 1 | 1988 | 5 | 0.020 |
Why?
|
| Eating | 1 | 2008 | 34 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2009 | 152 | 0.020 |
Why?
|
| Poland | 1 | 2007 | 3 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 51 | 0.020 |
Why?
|
| Iceland | 1 | 2007 | 1 | 0.020 |
Why?
|
| Cladosporium | 1 | 1997 | 1 | 0.020 |
Why?
|
| Mites | 1 | 1997 | 1 | 0.020 |
Why?
|
| Pollen | 1 | 1997 | 1 | 0.020 |
Why?
|
| Cats | 1 | 1997 | 8 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 120 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 1997 | 19 | 0.020 |
Why?
|
| Austria | 1 | 2007 | 1 | 0.020 |
Why?
|
| Pacific States | 1 | 2006 | 4 | 0.020 |
Why?
|
| Grief | 1 | 1986 | 3 | 0.020 |
Why?
|
| ROC Curve | 1 | 2006 | 73 | 0.020 |
Why?
|
| Caloric Restriction | 1 | 2006 | 4 | 0.020 |
Why?
|
| Carbon | 1 | 1986 | 3 | 0.020 |
Why?
|
| Death | 1 | 1986 | 10 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1986 | 31 | 0.020 |
Why?
|
| Complement C4 | 1 | 1986 | 1 | 0.020 |
Why?
|
| Complement C3 | 1 | 1986 | 2 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 1986 | 3 | 0.020 |
Why?
|
| Occupations | 1 | 1986 | 15 | 0.020 |
Why?
|
| Life Change Events | 1 | 1986 | 31 | 0.020 |
Why?
|
| Light | 1 | 1986 | 2 | 0.020 |
Why?
|
| Melatonin | 1 | 1986 | 4 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1986 | 104 | 0.020 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2005 | 2 | 0.020 |
Why?
|
| Respiratory System Agents | 1 | 2005 | 2 | 0.020 |
Why?
|
| Birth Order | 1 | 2005 | 4 | 0.020 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2005 | 3 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 13 | 0.020 |
Why?
|
| Maternal Age | 1 | 2005 | 74 | 0.020 |
Why?
|
| Dermatitis, Atopic | 1 | 2005 | 15 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2005 | 36 | 0.010 |
Why?
|
| Emotions | 1 | 2005 | 34 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 155 | 0.010 |
Why?
|
| Germany | 1 | 2004 | 14 | 0.010 |
Why?
|
| Multiphasic Screening | 1 | 2004 | 8 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 2004 | 43 | 0.010 |
Why?
|
| Homocysteine | 1 | 2003 | 11 | 0.010 |
Why?
|
| Kinetics | 1 | 2003 | 12 | 0.010 |
Why?
|
| School Health Services | 1 | 2004 | 39 | 0.010 |
Why?
|
| Cadaver | 1 | 1983 | 1 | 0.010 |
Why?
|
| Tissue Donors | 1 | 1983 | 7 | 0.010 |
Why?
|
| Cholesterol | 1 | 2003 | 82 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2002 | 30 | 0.010 |
Why?
|
| Japan | 2 | 1995 | 14 | 0.010 |
Why?
|
| Contraceptives, Oral | 1 | 1981 | 25 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1981 | 52 | 0.010 |
Why?
|
| Tuberculin Test | 1 | 2000 | 3 | 0.010 |
Why?
|
| Germ Cells | 1 | 1999 | 2 | 0.010 |
Why?
|
| Nuts | 1 | 1999 | 4 | 0.010 |
Why?
|
| Diet, Vegetarian | 1 | 1999 | 13 | 0.010 |
Why?
|
| Skin Tests | 1 | 1998 | 2 | 0.010 |
Why?
|
| Meat | 1 | 1997 | 27 | 0.010 |
Why?
|
| Food Additives | 1 | 1996 | 3 | 0.010 |
Why?
|
| Electric Impedance | 1 | 1995 | 7 | 0.010 |
Why?
|
| Ambulatory Care Facilities | 1 | 1995 | 66 | 0.010 |
Why?
|
| Dietary Proteins | 1 | 1995 | 19 | 0.010 |
Why?
|
| Dietary Fiber | 1 | 1995 | 60 | 0.010 |
Why?
|
| Maximum Allowable Concentration | 1 | 1993 | 1 | 0.010 |
Why?
|
| Drug Compounding | 1 | 1993 | 5 | 0.010 |
Why?
|
| Influenza, Human | 1 | 1996 | 282 | 0.010 |
Why?
|
| Hospital Bed Capacity, 100 to 299 | 1 | 1993 | 1 | 0.010 |
Why?
|
| Recovery Room | 1 | 1993 | 1 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1993 | 9 | 0.010 |
Why?
|
| Low Back Pain | 1 | 1993 | 57 | 0.010 |
Why?
|
| Information Systems | 1 | 1992 | 14 | 0.010 |
Why?
|
| United States Occupational Safety and Health Administration | 1 | 1992 | 1 | 0.010 |
Why?
|
| Research | 1 | 1992 | 61 | 0.010 |
Why?
|
| Trees | 1 | 1991 | 3 | 0.010 |
Why?
|
| Germany, West | 1 | 1990 | 1 | 0.010 |
Why?
|
| Cadmium | 1 | 1990 | 2 | 0.010 |
Why?
|
| Community Psychiatry | 1 | 1989 | 1 | 0.010 |
Why?
|
| Nursing Homes | 1 | 1988 | 10 | 0.000 |
Why?
|
| Death Certificates | 1 | 1988 | 17 | 0.000 |
Why?
|
| Biometry | 1 | 1987 | 14 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1986 | 38 | 0.000 |
Why?
|
| Respiration Disorders | 1 | 1986 | 5 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1986 | 107 | 0.000 |
Why?
|
| Radiography, Thoracic | 1 | 1986 | 18 | 0.000 |
Why?
|
| Sex Characteristics | 1 | 1986 | 66 | 0.000 |
Why?
|
| Utah | 1 | 1981 | 32 | 0.000 |
Why?
|